Overview

A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Status:
Not yet recruiting
Trial end date:
2030-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of RO7434656, a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropathy (IgAN) who are at high risk of progressive kidney disease despite optimized supportive care.
Phase:
Phase 3
Details
Lead Sponsor:
Hoffmann-La Roche